22NW LP Purchases Shares of 179,000 Keros Therapeutics, Inc. $KROS

Key Points

• 22NW LP has acquired a new stake in Keros Therapeutics, buying 179,000 shares valued at approximately $1.8 million, making it the fund's 16th largest holding.
• Recent analysts' ratings for Keros Therapeutics show mixed forecasts, with Bank of America downgrading the stock from "buy" to "neutral" and lowering the target price from $32 to $18.
• Keros Therapeutics reported a significant year-over-year revenue increase of 49002.7%, with a quarterly loss of ($0.76) earnings per share, beating the consensus estimate.

22NW LP purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 179,000 shares of the company's stock, valued at approximately $1,824,000. Keros Therapeutics makes up about 1.4% of 22NW LP's investment portfolio, making the stock its 16th biggest position. 22NW LP owned 0.44% of Keros Therapeutics as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Keros Therapeutics by 37.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,208 shares of the company's stock worth $241,000 after buying an additional 4,153 shares in the last quarter. Barclays PLC lifted its holdings in shares of Keros Therapeutics by 79.2% in the fourth quarter. Barclays PLC now owns 107,542 shares of the company's stock worth $1,703,000 after buying an additional 47,528 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Keros Therapeutics by 207.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after buying an additional 4,976 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Keros Therapeutics by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 155,163 shares of the company's stock worth $2,456,000 after buying an additional 2,727 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Keros Therapeutics by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after buying an additional 1,027 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KROS. Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank lowered their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. HC Wainwright lowered their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Stock Performance

Shares of KROS opened at $15.56 on Friday. The company's fifty day moving average is $14.04 and its 200 day moving average is $13.00. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market capitalization of $632.05 million, a PE ratio of 50.20, a P/E/G ratio of 1.91 and a beta of 1.33.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. During the same quarter in the previous year, the business posted ($1.25) earnings per share. Keros Therapeutics's quarterly revenue was up 49002.7% on a year-over-year basis. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.